Results of KEYNOTE-355 were presented at the 2021 San Antonio Breast ... affiliations with biotech, pharmaceutical, and/or device companies.
News
- KEYNOTE-355 Identifies PD-L1 Expression Cut-off for Pembrolizumab Benefit in mTNBC ...
- Study can't confirm lab results for many cancer experiments - mySA
San Antonio should reconsider those 'Edgar' haircut jokes ... a biotechnology consultant and former head of cancer research at drugmaker Amgen.
- OMG, omicron: Why I'm not panicking about the new variant - San Antonio Report
Following the opening of booster vaccinations, University Health pharmacy technicians pre-dose syringes of the Pfizer vaccine against COVID-19 ...
- Black women at greatest risk for breast cancer-related lymphedema - Healio
... to study results presented at San Antonio Breast Cancer Symposium. ... Immunomedics, Novartis, Pfizer, Puma Biotechnology and Seagen.
- HiberCell To Present New Data on Odetiglucan Plus Pembrolizumab in Ongoing Phase 2 ...
07, 2021 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, ...